Key points are not available for this paper at this time.
Abstract Breast cancer rates among women younger than 50 years-old have been steadily increasing since the mid-1990s. There is consistent evidence that use of combination estrogen and progesterone oral contraceptives (OCs) —including contemporary formulations with lower estrogen—increases breast cancer risk. It is unclear, however, if this risk varies by factors such as progestin type in the OC formulation, timing of OC use, histopathologic characteristics of the breast cancer, or individual patient characteristics. This study included premenopausal women aged 50 years and cancer-free when they enrolled in the U. S. -based American Cancer Society Cancer Prevention Study-3 cohort between 2006 and 2013 (n=101, 838 women). At enrollment participants responded to a detailed life history questionnaire including questions about type, brand, duration, and recency of OC use. Incident breast cancers diagnosed between 2006-2018 were identified through cancer registry linkages (n=759). Participants were followed until the first of 1) breast cancer diagnosis, 2) age 50 years, or 3) December 31, 2018. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate associations between OC use and breast cancer risk. On average, participants were 39. 3 years at baseline and were followed for 5. 7 years (up to 12. 3 years). Current versus never use of OCs for 10+ years was associated with a higher risk of breast cancer (10-20 years: HR=1. 46, 95% CI: 1. 03-2. 07; 20-30 years: HR=1. 66, 95% CI: 1. 14-2. 41; 30+ years HR= 2. 51, 95% CI: 0. 77-8. 16). Cessation of OC use progressively attenuated the association down to the null 15 years after discontinuation of use (HR=1. 04, 95% CI: 0. 73-1. 49). Associations with current OC use varied by generation of progestin in the formulation (first generation: HR=1. 37, 95% CI: 0. 93-2. 02; second: HR=1. 79, 95% CI: 1. 20-2. 67; third: HR=1. 65, 95% CI: 1. 13-2. 42; fourth: HR= 0. 91, 95% CI: 0. 49-1. 67). The strongest associations were observed for use of formulations with norgestrel: HR=2. 82, 95% CI: 1. 54-5. 19; norgestimate: HR=1. 80, 95% CI: 1. 19-2. 72; and levonorgestrel: HR=1. 56, 95% CI: 1. 00-2. 43. The OC-breast cancer associations were primarily limited to localized, grade 1 or 2, and ER+ disease. Race, income, body mass index, physical activity, alcohol use, cigarette smoking, parity, and breastfeeding did not appear to modify the associations. There were also no clear differences in the associations based on age at first or last OC use or timing relative to pregnancy. Current, long-term OC use was associated with increased risk of early-onset breast cancer. These data suggest that risks may vary with progestin content, and future studies are needed to define formulations that minimize breast cancer risk while still maximizing protection against other female cancers. Citation Format: Lauren R. Teras, Emily L. Deubler, Mark E. Sherman, Clara Bodelon, Lauren E. McCullough, James M. Hodge, Sicha Chantaprasopsuk, Alpa V. Patel. Factors modifying the association between hormonal contraception and risk of early-onset breast cancer abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 3442.
Teras et al. (Fri,) studied this question.